IFx-Hu2.0 Expanded Access Program

• Conditions: Cutaneous Melanoma, Stage III; Cutaneous Melanoma, Stage IV; Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma

• Registration Number: NCT04853602
• Lead Sponsor: TuHURA Biosciences, Inc.

Brief Summary

Expanded access requests for IFx-Hu2.0 may be considered for the treatment of adult patients (greater than or equal to 18 years of age) with stage III through IV cutaneous melanoma, advanced Merkel cell carcinoma (MCC), or advanced cutaneous squamous cell carcinoma (cSCC) who have failed all available treatment options.

To request access, use Responsible Party contact information provided in this record..

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-04-16
• Study First Submitted QC: 2021-04-16
• Study First Posted: 2021-04-21
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-08
• Last Update Posted: 2024-08-12

Recruitment & Eligibility

• Status: AVAILABLE
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• To request more information use Responsible Party contact information provided in this record

Exclusion Criteria

• To request more information use Responsible Party contact information provided in this record

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified